A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)
Giancarlo Comi(Vita-Salute San Raffaele University), Catherine Lubetzki(Centre National de la Recherche Scientifique), Marisa McGinley(Cleveland Clinic), Owain W. Howell(Hammersmith Hospital), Licínio Craveiro(Roche (Switzerland)), Helmut Butzkueven(Monash Alfred Psychiatry Research centre), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Letizia Leocani(Vita-Salute San Raffaele University), Maria Pia Sormani(University of Genoa), Douglas L. Arnold(University of Oxford), Guy Gherardi(Roche (Sweden)), Pavan Bhargava(Johns Hopkins University), Amit Bar‐Or(McGill University), Thomas Kuenzel(Université de Bordeaux), Christine Lebrun‐Frénay(Université Côte d'Azur), Agne Kazlauskaite(Roche (Sweden)), Roland Henry(University of California System), Declan Chard(National Institute for Health and Care Research), Robert A Bermel(Cleveland Clinic), Ralph Benedict(University at Buffalo, State University of New York), Finn Sellebjerg(Danish Multiple Sclerosis Center)
Cited by 5
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k